Coupling FcRn Recycling with TMDD

Why FcRn Salvage and TMDD Must Be Coupled

Antibody disposition can involve two processes with different consequences for antibody loss. In endosomes, binding to the neonatal Fc receptor (FcRn) can return antibody to the circulation instead of allowing it to be degraded. Separately, binding to a target can form a complex that is internalized, removing the bound antibody. These pathways are coupled because they both draw on the same free-antibody pool: changing either pathway changes free antibody available to the other.

A useful model must distinguish binding from irreversible loss. FcRn binding is not itself a loss if the bound antibody dissociates or is recycled. Likewise, target association is not by itself a permanent loss: antibody may dissociate from the complex. In this model, complex internalization is the target-mediated loss process, while endosomal degradation is the competing loss process.

A Coupled Mass-Balance Model

Assume antibody enters the central space at rate \(u(t)\), with concentration-per-time units. Free antibody is cleared from that space at first-order rate constant \(k_{\mathrm{cl}}\) and enters the endosomal space at rate \(k_u A\). In the endosome, free antibody is degraded at rate \(k_{\mathrm{deg}}E\), and binds FcRn with association rate constant \(k_{\mathrm{on,F}}\). FcRn-bound antibody dissociates at rate \(k_{\mathrm{off,F}}\) or returns to the central space at rate \(k_{\mathrm{ret}}\). FcRn is treated as a fixed pool of total concentration \(N\).

For the target pathway, assume reversible 1:1 binding with association and dissociation rate constants \(k_{\mathrm{on,T}}\) and \(k_{\mathrm{off,T}}\). Complex is internalized at rate \(k_{\mathrm{int}}C\). Target is synthesized at rate \(k_{\mathrm{syn,R}}\) and turns over when free at first-order rate constant \(k_{\mathrm{deg,R}}\). Internalization removes both antibody and target in complex.

This formulation assumes well-mixed effective compartments, fixed kinetic rate constants, one FcRn-binding site per antibody in the endosomal subsystem, and one target-binding site in the TMDD subsystem. It does not include FcRn turnover, target distribution among tissues, or antibody binding to other targets. Those processes would require additional states or terms.

Exact Antibody Mass Balance

The individual equations contain several binding and transport terms that move antibody between states rather than remove it. Add the first four equations, defining total tracked antibody concentration as \(D=A+E+F+C\). Central-to-endosomal uptake cancels with its appearance in \(E\); FcRn binding and dissociation cancel between \(E\) and \(F\); target binding and dissociation cancel between \(A\) and \(C\). The return flux \(k_{\mathrm{ret}}F\) also cancels between the endosomal state and the central state.

This identity is an important check on an implementation: only input, central clearance, endosomal degradation, and complex internalization change the amount of tracked antibody. At steady state under constant input \(u\), the input must equal the sum of these loss fluxes. The binding rates can change those losses indirectly by changing the amounts in each state, but binding alone is not a loss.

A useful reduced description is available when the endosomal states and target complex adjust rapidly relative to changes in central free antibody. This is a quasi-steady-state assumption, not a claim that the entire system is at steady state. Set \(dF/dt\) approximately to zero and define the effective FcRn constant \(K_F=(k_{\mathrm{off,F}}+k_{\mathrm{ret}})/k_{\mathrm{on,F}}\). Then:

If \(dE/dt\) is also approximately zero, the FcRn binding relation gives \(k_{\mathrm{on,F}}E(N-F)-k_{\mathrm{off,F}}F=k_{\mathrm{ret}}F\). Substitution into the \(E\) equation therefore yields the endosomal balance \(k_uA=k_{\mathrm{deg}}E+k_{\mathrm{ret}}F\). Uptake is divided between degradation and return; it is not correct to count the FcRn association flux itself as salvage.

For the target subsystem, if \(dC/dt\) is approximately zero, then \(C=k_{\mathrm{on,T}}AR/(k_{\mathrm{off,T}}+k_{\mathrm{int}})\). At steady target abundance, the target equation becomes:

The added denominator term is the net target removal caused by complex internalization. Dissociation returns target to the free pool; it does not remove target. These reductions are useful when their timescale assumptions are reasonable, but the full differential equations are needed when the states change on comparable timescales.

Worked Pathway Calculations

The following examples use hypothetical parameter values. Each calculates the pathway fluxes compatible with a specified free-antibody concentration; it does not represent an observed study. Rate constants are in hours\(^{-1}\) unless otherwise indicated, and concentrations are in nM.

Interpreting, Checking, and Comparing Models

The coupled model separates the mechanisms while preserving their interaction through \(A\). A convenient steady-state accounting is:

The terms on the right are distinct antibody-loss fluxes. The model can compare their magnitudes at a specified condition, but flux contributions are not automatically equal to causal contributions to a change in exposure. A parameter change can alter several states and fluxes simultaneously.

A useful diagnostic is to calculate the endosomal residual \(k_uA-k_{\mathrm{deg}}E-k_{\mathrm{ret}}F\) under the endosomal quasi-steady-state approximation. It should be near zero relative to the flux scale. For a full dynamic simulation, check instead that the sum of the state derivatives agrees with the exact total-antibody balance. Also check \(0\leq F\leq N\), nonnegative concentrations, and units: for example, \(k_{\mathrm{int}}C\) must have concentration-per-time units.

The coupled model is more informative than adding two independent clearance terms to a one-state antibody model. Such an additive approximation may be useful over a narrow concentration range if its effective clearances are calibrated there, but it can miss changes in endosomal partitioning, target occupancy, and free antibody. Conversely, a full ODE model may be unnecessary when endosomal and complex states equilibrate rapidly; a quasi-steady reduction can be more efficient, provided its timescale assumptions are checked. Neither approach removes uncertainty about the model’s structural assumptions or parameter values.

Common Pitfalls and Limitations

• Counting binding as loss. FcRn association and target association move antibody between modeled states. Count degradation and complex internalization as losses; do not count association fluxes as additional clearance.
• Using the FcRn pool as if it were unlimited. The expression \(F=NE/(K_F+E)\) enforces \(F\leq N\). A linear approximation to this relation is only defensible when \(E\) is small relative to \(K_F\).
• Confusing free and total measurements. An assay measuring only \(A\) does not directly measure \(A+E+F+C\). Interpret a reported concentration in light of which states the assay detects.
• Applying quasi-steady state without a timescale check. If \(F\), \(E\), or \(C\) changes slowly relative to \(A\), setting its derivative to zero can distort transient predictions even if the reduced model gives plausible steady-state fluxes.
• Ignoring target feedback. With target turnover, free target \(R\) can change as complexes form and internalize. Holding \(R\) fixed is a separate approximation, not a consequence of TMDD itself.

The model is a mechanistic accounting framework, not a guarantee that each pathway is identifiable from a particular dataset. Similar changes in observed antibody exposure can arise from different combinations of recycling, degradation, binding, and internalization. Its predictions also depend on the chosen compartment structure, the assumed fixed FcRn pool, and the accuracy of the rate constants.